vepdegestrant
Small moleculeexperimental
Clinical trial activity
22 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
16
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Aug 5, 2019 (NCT04072952)
Timeline
Indications
Mechanism of action
- Estrogen receptor alphaDEGRADER
ESR1 degrader
Chemistry & pharmacology
Loading structure…
SMILES
O=C1CC[C@H](N2Cc3cc(N4CCN(CC5CCN(c6ccc([C@@H]7c8ccc(O)cc8CC[C@@H]7c7ccccc7)cc6)CC5)CC4)ccc3C2=O)C(=O)N1- Mol. weight
- 723.92 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095210 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07231991 | Phase 1 | Nov 4, 2025 | Arvinas Inc, Pfizer |
| NCT06911788 | Phase 1 | Apr 3, 2025 | Arvinas Inc, Pfizer |
| NCT06645938 | Phase 1 | Oct 24, 2024 | Arvinas Inc, Pfizer |
| NCT06347861 | Phase 1 | Apr 2, 2024 | Arvinas Inc, Pfizer |
| NCT06275841 | Phase 1 | Feb 23, 2024 | Arvinas Inc, Pfizer |
| NCT06206837 | Phase 1/Phase 2 (Phase 2) | Feb 19, 2024 | Arvinas Inc, Pfizer |
| NCT06256510 | Phase 1 | Feb 8, 2024 | Arvinas Inc, Pfizer |
| NCT06125522 | Phase 2 | Nov 10, 2023 | Arvinas Inc, Carrick Therapeutics Limited, Pfizer |
| NCT06005688 | Phase 1 | Aug 18, 2023 | Arvinas Inc, Pfizer |
| NCT05909397 | Phase 3 | Aug 9, 2023 | Arvinas Inc, Pfizer |
| NCT05930925 | Phase 1 | Jun 12, 2023 | Arvinas Inc, Pfizer |
| NCT05732428 | Phase 1 | Feb 20, 2023 | Arvinas Inc, Pfizer |
| NCT05673889 | Phase 1 | Jan 27, 2023 | Arvinas Inc, Pfizer |
| NCT05538312 | Phase 1 | Jan 14, 2023 | Arvinas Inc, Pfizer |
| NCT05549505 | Phase 2 | Dec 31, 2022 | Arvinas Inc, Pfizer |
| NCT05654623 | Phase 3 | Dec 15, 2022 | Arvinas Inc, Pfizer |
| NCT05652660 | Phase 1 | Dec 9, 2022 | Arvinas Inc, Pfizer |
| NCT05573555 | Phase 2 | Dec 9, 2022 | Arvinas Inc, Pfizer |
| NCT05548127 | Phase 2 | Dec 9, 2022 | Arvinas Inc, Pfizer |
| NCT05501769 | Phase 1 | Sep 8, 2022 | Arvinas Inc, Pfizer |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arvinas Inc | For profit | 22 | 3 | 3 | 2019 |
| Pfizer | For profit | 21 | 19 | 3 | 2022 |
| Carrick Therapeutics Limited | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1